Expert review of respiratory medicineHumansAsthmaAnti-Asthmatic AgentsBiological ProductsPhenotype
Advances in type 2-high asthma therapy: what remains missing?
Ahmad Z Al Meslamani, Anan S Jarab, Abdullah Elrefae
Published: 202610.1080/17476348.2025.2569844
Abstract
INTRODUCTION: Type 2-high asthma (T2HA) accounts for most severe asthma morbidity and is driven by eosinophilic, IgE- and alarmin-mediated inflammation. Although five biologics are licensed, many patients remain symptomatic, corticosteroid-dependent…
Preview only. Read the full abstract at the source